Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedMar 05, 2026
DataAggregated Company Financials
Companies21
  • 7D2.0%
  • 3M-18.5%
  • 1Y-54.2%
  • YTD-22.1%

The Healthcare industry is up 2.0% in the last week, with Novo Nordisk up 3.8%. In contrast, the industry has lost 54% in the last 12 months. As for the next few years, earnings are expected to grow by 4.4% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 05 Mar 2026DKK 1.5tDKK 448.1bDKK 131.0b17.8x11.6x3.4x
Sat, 31 Jan 2026DKK 2.1tDKK 453.4bDKK 136.7b17.6x15.5x4.7x
Mon, 29 Dec 2025DKK 2.0tDKK 453.7bDKK 136.8b17.1x14.4x4.3x
Wed, 26 Nov 2025DKK 1.8tDKK 454.2bDKK 137.0b17.5x13.4x4x
Fri, 24 Oct 2025DKK 2.0tDKK 447.8bDKK 141.8b18.8x14.4x4.5x
Sun, 21 Sep 2025DKK 2.2tDKK 447.3bDKK 141.7b19x15.7x5x
Tue, 19 Aug 2025DKK 2.0tDKK 444.5bDKK 140.3b28.3x14.3x4.5x
Thu, 17 Jul 2025DKK 2.4tDKK 423.2bDKK 124.5b29.9x19.1x5.6x
Sat, 14 Jun 2025DKK 2.8tDKK 423.4bDKK 124.6b31.4x22.3x6.5x
Mon, 12 May 2025DKK 2.4tDKK 423.4bDKK 124.9b22.6x19.4x5.7x
Wed, 09 Apr 2025DKK 2.4tDKK 409.4bDKK 121.3b21.8x19.6x5.8x
Fri, 07 Mar 2025DKK 3.2tDKK 409.5bDKK 121.3b27.3x26.6x7.9x
Sun, 02 Feb 2025DKK 3.3tDKK 387.7bDKK 111.4b28.8x29.2x8.4x
Tue, 31 Dec 2024DKK 3.3tDKK 387.4bDKK 111.3b29.9x29.6x8.5x
Thu, 28 Nov 2024DKK 3.9tDKK 387.3bDKK 111.3b31.3x34.7x10x
Sat, 26 Oct 2024DKK 4.1tDKK 372.2bDKK 107.2b34x37.9x10.9x
Mon, 23 Sep 2024DKK 4.4tDKK 371.9bDKK 107.1b37.4x40.8x11.8x
Wed, 21 Aug 2024DKK 4.6tDKK 370.6bDKK 107.0b36.2x43.4x12.5x
Fri, 19 Jul 2024DKK 4.5tDKK 355.2bDKK 106.2b35.5x42.5x12.7x
Sun, 16 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b35.5x46.7x14x
Tue, 14 May 2024DKK 4.6tDKK 354.9bDKK 106.0b34.9x43.6x13x
Thu, 11 Apr 2024DKK 4.4tDKK 341.2bDKK 99.6b37.3x44.6x13x
Sat, 09 Mar 2024DKK 4.7tDKK 341.2bDKK 99.6b39.6x46.7x13.6x
Mon, 05 Feb 2024DKK 4.0tDKK 338.6bDKK 98.5b32.7x40.6x11.8x
Wed, 03 Jan 2024DKK 3.6tDKK 320.5bDKK 90.0b33x40.3x11.3x
Fri, 01 Dec 2023DKK 3.6tDKK 320.5bDKK 90.0b33.2x40.2x11.3x
Sun, 29 Oct 2023DKK 3.4tDKK 305.6bDKK 82.3b26.6x41.5x11.2x
Tue, 26 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b33.2x41x11x
Thu, 24 Aug 2023DKK 3.4tDKK 305.1bDKK 82.1b35.4x42x11.3x
Sat, 22 Jul 2023DKK 3.0tDKK 287.0bDKK 75.4b40.6x40.1x10.6x
Mon, 19 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40.5x40.3x10.6x
Wed, 17 May 2023DKK 3.2tDKK 284.8bDKK 74.9b42x42.1x11.1x
Fri, 14 Apr 2023DKK 3.1tDKK 272.5bDKK 68.5b42.7x45x11.3x
Sun, 12 Mar 2023DKK 2.8tDKK 292.6bDKK 69.2b38.2x40.2x9.5x
Price to Earnings Ratio

40.2x


Total Market Cap: DKK 2.8tTotal Earnings: DKK 69.2bTotal Revenue: DKK 292.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 32.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.6x which is lower than its 3-year average PE of 32.6x.
  • The 3-year average PS ratio of 9.2x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 24% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market0.65%
Healthcare2.03%
Life Sciences15.49%
Pharma2.94%
Healthtech1.17%
Biotech-1.46%
Medical Equipment-1.67%
Healthcare Services-7.36%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 418x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 85% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Biotech industry is expected to see its earnings decline by 2.8% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 248.654.2%
+DKK 44.3b		-59.4%PE10.8x
ALK B ALK-AbellóDKK 225.007.1%
+DKK 3.3b		57.9%PE41.6x
GUBRA GubraDKK 395.8019.9%
+DKK 1.1b		-22.1%PE3.8x
ZEAL Zealand PharmaDKK 369.202.6%
+DKK 649.6m		-32.7%PE4x
CHEMM ChemoMetecDKK 420.601.8%
+DKK 132.3m		-24.8%PE41.3x

Latest News

CHEMM
DKK 420.60
ChemoMetec
7D
1.8%
1Y
-24.8%
GUBRA
DKK 395.80
Gubra
7D
19.9%
1Y
-22.1%
BAVA
DKK 187.60
Bavarian Nordic
7D
-4.7%
1Y
12.0%

BAVA: Buybacks And Latin America Vaccine Deal Will Drive Future Upside

Analysts have maintained their DKK 250 price target on Bavarian Nordic, citing only minor adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E as the reasons for this stable assessment. What's in the News CEO Paul Chaplin plans to step down for personal reasons, and the Board has agreed that he will stay in the role through the end of 2026 or until a successor is appointed.
NOVO B
DKK 248.65
Novo Nordisk
7D
4.2%
1Y
-59.4%
AMBU B
DKK 77.05
Ambu
7D
-3.3%
1Y
-38.8%
GMAB
DKK 1,775.00
Genmab
7D
-3.2%
1Y
8.2%

GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook

Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.
PEG
DKK 0.092
Pharma Equity Group
7D
-11.2%
1Y
-33.5%
COLO B
DKK 461.70
Coloplast
7D
-4.1%
1Y
-37.5%

COLO B: Reset P/E And Dividend Will Support Future Re Rating

Analysts have trimmed their DKK price targets on Coloplast, reflected in a lower fair value estimate from DKK 615 to DKK 588, as they factor in slightly more cautious assumptions on growth, margins and future P/E multiples following recent target reductions from several research houses. Analyst Commentary Bullish Takeaways Bullish analysts still see room for upside from current levels, even with reduced DKK price targets.
ALK B
DKK 225.00
ALK-Abelló
7D
7.1%
1Y
57.9%

ALK B: Future Returns Will Rely On Expanded Anaphylaxis Indications And Stronger Margins

Analysts have nudged their price target on ALK-Abelló up from DKK 249 to DKK 255, reflecting updated assumptions that combine slightly lower expected revenue growth with a higher projected profit margin and a modestly lower future P/E multiple. What's in the News ALK Abelló issued earnings guidance for 2026, indicating an expectation of continued double digit revenue growth and higher earnings, with revenue projected to grow 11 to 15% in local currencies (company guidance).
ZEAL
DKK 369.20
Zealand Pharma
7D
2.6%
1Y
-32.7%

ZEAL: Positive Immunology Data And Metabolic Partnership Will Support Future Upside

Analysts have trimmed their price target on Zealand Pharma by DKK 5 to reflect updated assumptions for revenue growth, profit margins and a higher forward P/E. They have kept the overall discount rate broadly in line with prior views.
EMBLA
DKK 29.60
Embla Medical hf
7D
-2.0%
1Y
-3.3%

EMBLA: Share Cancellations And Buybacks Will Support Future Upside Potential

Analysts have kept their DKK price target for Embla Medical hf broadly stable at around DKK 37.4, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that slightly adjust the risk and earnings profile without changing their overall valuation view. What's in the News The Annual General Meeting on 10 March 2026 will vote on reducing share capital by cancelling 2,441,257 treasury shares of ISK 1 each, equal to 0.57% of current share capital, with a corresponding update to Article 4 of the Articles of Association (Key Developments).
DEMANT
DKK 188.30
Demant
7D
-3.7%
1Y
-25.8%

DEMANT: Recent Rating Upgrade May Support Future Upside Despite Softer Margins

The updated analyst price target for Demant has moved slightly lower to about DKK 232 from roughly DKK 238, as analysts balance a modestly higher assumed revenue growth rate against slightly softer margin expectations and a higher discount rate, with recent Street research showing a mix of target cuts from several banks and one upgrade to Buy at DKK 230. Analyst Commentary Recent Street research around Demant reflects a split view, with one Upgrade to Buy around DKK 230 contrasting with several lower price targets and at least one downgrade.
HLUN B
DKK 38.36
H. Lundbeck
7D
-0.05%
1Y
-2.4%

HLUN B: Positive Neuroscience Pipeline Data Will Support Constructive Medium Term Outlook

Analysts have trimmed their DKK price target on H. Lundbeck from about DKK 47.05 to DKK 44.95, citing updated assumptions for revenue growth, profit margins, as well as a slightly higher future P/E multiple and discount rate.
NNIT
DKK 40.35
NNIT
7D
2.4%
1Y
-47.3%
BIOPOR
DKK 0.94
BioPorto
7D
7.5%
1Y
-39.5%
BRAINP
DKK 0.003
Brain+
7D
15.4%
1Y
-92.3%